ASCENDIS PHARMA BONE DISEASES A/S - CVR: 32323596

2023, EUR

03.04.2024

Bruttoresultat

-66.598'

Primær drift

-66.715'

Årets resultat

-72.198'

Aktiver

18.541'

Kortfristede aktiver

4.460'

Egenkapital

-249''

Afkastningsgrad

-360 %

Soliditetsgrad

-1344 %

Likviditetsgrad

+500%

Resultat

03.04.2024

Årsrapport	2023 03.04.2024	2022 24.03.2023	2021 09.05.2022	2020 29.03.2021	2019 11.05.2020	2018 22.05.2019	2017 18.05.2018	2016 11.05.2017
Nettoomsætning
Bruttoresultat	-66.598.343	-57.981.885	-38.797.098	-27.475.665	-18.881.606	-16.157.965	-6.444.960	-137.219
Resultat af primær drift	-66.714.825	-58.098.495	-38.913.324	-27.592.829	-18.976.198	-16.244.944	-6.531.527	0
Indtægter af kapitalandele (tilknyttede og associerede)	0	0	0	0	0	0	0	0
Finansielle indtægter	2	0	0	273	0	0	393	585
Finansieringsomkostninger	-5.584.669	-3.867.866	-2.468.634	-1.543.397	-868.887	-379.017	-102.551	-57.654
Andre finansielle omkostninger	0	0	0	0	0	0	0	0
Resultat før skat	-72.299.492	-61.966.361	-41.381.958	-29.135.953	-19.845.085	-16.623.961	-6.633.685	-279.468
Resultat	-72.197.542	-61.825.261	-41.299.834	-28.817.684	-19.845.085	-16.623.961	-6.620.900	-278.875
Forslag til udbytte	0	0	0	0	0	0	0	0

Aktiver

03.04.2024

Årsrapport	2023 03.04.2024	2022 24.03.2023	2021 09.05.2022	2020 29.03.2021	2019 11.05.2020	2018 22.05.2019	2017 18.05.2018	2016 11.05.2017
Kortfristede varebeholdninger	0	0	0	0	0	0	0	0
Kortfristede tilgodehavender fra salg og tjenesteydelser	4.413.855	4.227.036	4.011.136	3.873.194	2.254.793	1.882.847	1.068.934	4.685
Likvider	46.118	2.451	3.174.848	578	117.518	1.162.027	12.089	88.955
Kortfristede aktiver	4.459.973	4.229.487	7.185.984	3.873.772	2.372.311	3.044.874	1.081.023	93.640
Immaterielle aktiver og goodwill	0	0	0	0	85.715	171.429	257.143	146.940
Finansielle anlægsaktiver	14.065.145	14.065.145	10.881.827	10.881.827	10.881.827	0	0	0
Materielle aktiver	16.275	44.175	72.075	99.975	127.875	0	0	0
Langfristede aktiver	14.081.420	14.109.320	10.953.902	10.981.802	11.095.417	171.429	257.143	146.940
Aktiver	18.541.393	18.338.807	18.139.886	14.855.574	13.467.728	3.216.303	1.338.166	240.580

Aktiver

03.04.2024

Passiver

03.04.2024

Årsrapport	2023 03.04.2024	2022 24.03.2023	2021 09.05.2022	2020 29.03.2021	2019 11.05.2020	2018 22.05.2019	2017 18.05.2018	2016 11.05.2017
Forslag til udbytte	0	0	0	0	0	0	0	0
Egenkapital	-249.169.766	-176.972.224	-115.146.963	-73.847.129	-45.029.445	-25.184.360	-8.560.399	-1.939.500
Hensatte forpligtelser	0	0	0	0	0	0	0	0
Langfristet gæld til banker	0	0	0	0	0	0	0	0
Anden langfristet gæld	0	0	0	0	0	0	0	0
Leverandører af varer og tjenesteydelser	0	0	0	0	0	0	0	0
Kortfristede forpligtelser	5.916	5.877	4.740.050	3.512.640	8.294.713	1.112.703	501.924	4.700
Gældsforpligtelser	267.711.159	195.311.031	133.286.849	88.702.703	58.497.173	28.400.663	9.898.565	2.180.080
Forpligtelser	267.711.159	195.311.031	133.286.849	88.702.703	58.497.173	28.400.663	9.898.565	2.180.080
Passiver	18.541.393	18.338.807	18.139.886	14.855.574	13.467.728	3.216.303	1.338.166	240.580

Passiver

03.04.2024

Nøgletal

03.04.2024

Årsrapport	2023 03.04.2024	2022 24.03.2023	2021 09.05.2022	2020 29.03.2021	2019 11.05.2020	2018 22.05.2019	2017 18.05.2018	2016 11.05.2017
Afkastningsgrad	-359,8 %	-316,8 %	-214,5 %	-185,7 %	-140,9 %	-505,1 %	-488,1 %	Na.
Dækningsgrad	Na.	Na.	Na.	Na.	Na.	Na.	Na.	Na.
Resultatgrad	Na.	Na.	Na.	Na.	Na.	Na.	Na.	Na.
Varelagerets omsætningshastighed	Na.	Na.	Na.	Na.	Na.	Na.	Na.	Na.
Egenkapitals-forretning	29,0 %	34,9 %	35,9 %	39,0 %	44,1 %	66,0 %	77,3 %	14,4 %
Payout-ratio	Na.	Na.	Na.	Na.	Na.	Na.	Na.	Na.
Gældsdæknings-nøgletal	-1.194,6 %	-1.502,1 %	-1.576,3 %	-1.787,8 %	-2.184,0 %	-4.286,1 %	-6.369,1 %	Na.
Soliditestgrad	-1.343,9 %	-965,0 %	-634,8 %	-497,1 %	-334,4 %	-783,0 %	-639,7 %	-806,2 %
Likviditetsgrad	75.388,3 %	71.966,8 %	151,6 %	110,3 %	28,6 %	273,6 %	215,4 %	1.992,3 %

Resultat

03.04.2024

Gæld

03.04.2024

Årsrapport

03.04.2024

Nyeste:01.01.2023- 31.12.2023(offentliggjort: 03.04.2024)

Beretning

03.04.2024

Dato for ledelsens godkendelse af årsrapporten:2023-02-24

Oplysning om usædvanlige forhold:Impact from Covid-19 Pandemic The COVID-19 pandemic has affected countries where we are operating, where we have planned or have ongoing clinical trials, and where we rely on third-parties to manufacture preclinical, and clinical supply. While COVID-19 had an impact on how we work and conduct our activities, we have managed to avoid significant disruptions to our clinical and manufacturing operations. We monitor the risks from the pandemic closely, and work with relevant stakeholders to avoid and limit disruptions, and to develop and establish working measures. However, while COVID-19 continues to impact global societies, the uncertainty related to the duration and direction of the pandemic makes the future impact from COVID-19, including the magnitude of any impact on our operational results, highly uncertain and unpredictable. Impact from Conflict in Ukraine The military conflict between Russia and Ukraine has increased the likelihood of supply interruptions and made it difficult to conduct business operations, including clinical trials, in the region and in nearby countries. We originally planned to conduct the Phase 3 foresiGHt trial utilizing sites in Belarus and Russia, but instead we engaged with alternative sites for the study following the outbreak of conflict in Ukraine, which adversely affected patient enrollment. Such developments could negatively impact such operations or require us to delay or suspend clinical trial activities, which may increase product development costs and harm our business. We will continue to closely monitor the rapidly evolving geopolitical situation in Ukraine and Russia and its impact on our clinical trial operations and timelines.

Statement by Management on the annual report

Identifikation af den godkendte årsrapport:The Executive Board and Board of Directors have today considered and adopted the Annual Report of Ascendis Pharma Bone Diseases A/S for the financial year 1 January - 31 December 2022.